加速大分割质子治疗同步化疗治疗局部晚期非小细胞肺癌的Ⅰ期研究
这项Ⅰ期试验采用时间-事件连续重评估方法,评估大分割质子束放疗同步每周卡铂/紫杉醇在Ⅱ-Ⅲ期非小细胞肺癌中的最大耐受剂量。2015年5月至2016年9月单机构入组23例,20例可评估;6个月评估窗内未报告方案规定的严重不良事件,60 Gy组剂量限制性毒性后验概率为5.3%(95%CI 1%-18.1%)。结论认为至60 Gy/15次的大分割质子放疗同步化疗急性期耐受良好,局控和总生存率高,但观察到晚期严重不良事件。
要点
- 60 Gy/15次组剂量限制性毒性后验概率为5.3%(95%CI 1%-18.1%),6个月评估窗内未报告方案规定的严重不良事件。
- 急性非严重不良事件包括2级食管炎7例(35%)和2级肺炎1例(5%)。
- 中位随访20.3个月,全组无4级或5级不良事件,但剂量爬坡窗之外发生3例严重不良事件(24个月时21%)。
核心结论
- 大分割质子束放疗同步化疗至60 Gy/15次急性期耐受良好,局控率和总生存率高,但观察到晚期严重不良事件。
研究设计与样本
- 采用时间-事件连续重评估方法设计的Ⅰ期试验,最大耐受剂量定义为方案规定的常见不良事件评价标准严重不良事件概率为20%所对应的剂量。
- 起始剂量为3.5 Gy/次共15次,设2个爬坡和降坡水平,按0.25 Gy/次递增。
- 化疗为每周同步卡铂/紫杉醇,另可选2周期巩固卡铂/紫杉醇。
- 2015年5月至2016年9月单机构入组23例,20例可评估;中位年龄66.5岁(范围54-89岁),男性12例(60%)。
- 14例(70%)为鳞癌,15例(75%)为ⅢA期。
主要发现
- 19例(95%)完成全部3周期同步化疗,16例(80%)接受至少1周期巩固化疗。
- 6个月时间-事件连续重评估方法评估窗内未报告严重不良事件,多数患者接受最高剂量水平治疗。
- 剂量水平分配为52.5 Gy(n=2)、56.25 Gy(n=4)和60 Gy(n=14)。
- 60 Gy的剂量限制性毒性后验概率为5.3%(95%CI 1%-18.1%)。
- 急性非严重不良事件包括2级食管炎7例(35%)和2级肺炎1例(5%);全组中位随访20.3个月、存活患者中位随访44.9个月,无4级或5级不良事件,但剂量爬坡窗之外发生3例严重不良事件(24个月时21%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our purpose was to evaluate the maximum tolerated dose of hypofractionated proton beam radiation therapy with concurrent weekly carboplatin/paclitaxel in patients with stage II-III non-small cell lung cancer. METHODS AND MATERIALS: A phase I trial was designed using the time-to-event continuous reassessment method. Maximum tolerated dose was defined as the dose associated with a 20% probability of Common Terminology Criteria for Adverse Events protocol-specified serious adverse events (SAEs). Starting dose was 3.5 Gy/fx for 15 fractions with 2 potential escalation and de-escalation levels in 0.25 Gy/fx increments. Chemotherapy was weekly concurrent carboplatin/paclitaxel with 2 cycles of optional consolidation carboplatin/paclitaxel. RESULTS: From May 2015 to September 2016, 23 patients enrolled at a single institution. Of 20 evaluable, median age was 66.5 years (range, 54-89) and 12 were male (60%). Fourteen (70%) had squamous cell and 15 (75%) were stage IIIA. Nineteen (95%) completed all 3 cycles of concurrent chemotherapy, and 16 (80%) received at least 1 cycle of consolidation chemotherapy. Within the 6-month time-to-event continuous reassessment method assessment window, no SAEs were reported, and most patients were treated at the highest dose level. Dose level assignment was 52.5 Gy (n = 2), 56.25 Gy (n = 4), and 60 Gy (n = 14). The posterior probability of dose-limiting toxicity for 60 Gy was 5.3% (95% confidence interval, 1%-18.1%). Acute, nonserious AEs included grade 2 esophagitis in 7 patients (35%) and grade 2 pneumonitis in 1 patient (5%). At a median follow-up of 20.3 months for all and 44.9 months for living patients, there were no grade 4 or 5 AEs, though there were 3 (21% at 24 months) SAEs outside of the dose-escalation window. The 2-year overall survival, local, regional, and distant control rates were 48%, 84%, 77%, and 79%, respectively. CONCLUSIONS: Hypofractionated proton beam radiation therapy and chemotherapy up to 60 Gy in 15 fractions is acutely well tolerated, with high rates of locoregional control and overall survival, though late SAEs were noted.
引用
- Contreras J, Srivastava A, Samson P, et al. Phase I Study of Accelerated Hypofractionated Proton Therapy and Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2022. PMID: 35074432. doi:10.1016/j.ijrobp.2022.01.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。